Investigator Initiated Trials Increasingly Impacted by FMV Concerns

New Study Identifies Potential Improvement Opportunities

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Investigator initiated trial (IIT) management teams must incorporate fair-market value (FMV) into their payment protocols to appropriately respond to regulatory scrutiny and maintain compliance, according to a new study by Cutting Edge Information.

According to “Investigator Initiated Trial Management,” 23% of study participants ranked oversight or intervention from the Office of Inspector General (OIG) as their number one IIT management challenge. In response to regulatory pressures, many top drug makers have been forced to sign corporate integrity agreements (CIAs) with the OIG, a costly move requiring them to establish formal processes surrounding thought leader interactions.

“Scrutiny over payments has affected all physician-facing functions in the life sciences industry, but as IITs grow increasingly important to corporate strategy, it’s equally important that medical affairs teams standardize practices and follow FMV protocol,” said Ryan McGuire, senior research analyst at Cutting Edge Information and the study’s lead author.

The study identified three key improvement opportunities to avoid direct OIG oversight. First, FMV analysis must become a formal part of the IIT proposal review process, and teams should check the investigator’s budgets against databases of clinical trial costs. Second, companies should invest in documentation tools that accurately monitor aggregate spending to avoid overpaying. Third, companies should use milestone payments to track investigator services.

“Executives interviewed for this study said investigators are too often unaware of the extent that regulatory rules determine standard operating procedures, as well as their own responsibility to conduct a compliant study,” said Adam Bianchi, chief operating officer of Cutting Edge Information.

“With sound practices agreed upon by global, regional and subfunction leadership, IITs are well-positioned to create a strategic ‘meeting of the minds’ of medical affairs and clinical development strengths.”

The new study (http://www.cuttingedgeinfo.com/research/medical-affairs/investigator-initiated-trials/) contains benchmarks and best practices to reinforce IIT management and execution from proposal submission through study completion. The data include IIT team structures, budgets and spending, and team goals and challenges. The information focuses on key goals identified by benchmarking partners:

  • Use digital systems to accelerate and streamline proposal receipt, review and approval.
  • Meet growing needs with dedicated resources and appropriate spending to ensure smooth operations.
  • Build a standardized structure to manage and track IITs.
  • Align objectives for study conclusion and the use of data findings with product strategy.



CONTACT:

Cutting Edge Information
Elio Evangelista, 919-403-6583

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Nearly 10,000 patients involved in research studies were impacted by a third-party privacy breach that may have exposed their medical diagnoses, test results…

Veterans Health Administration medical facilities currently have a paper medical record backlog that if stacked up would be 5.15 miles high, according to the…

The Department of Health and Human Services announced proposed changes to privacy restrictions on patients' substance use treatment records.